Ameriprise’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.18B | Buy |
2,633,481
+369,749
| +16% | +$172M | 0.27% | 81 |
|
|
2025
Q4 | $1.03B | Sell |
2,263,732
-13,195
| -0.6% | -$5.69M | 0.23% | 85 |
|
|
2025
Q3 | $892M | Buy |
2,276,927
+95,565
| +4% | +$39.9M | 0.2% | 100 |
|
|
2025
Q2 | $971M | Sell |
2,181,362
-54,107
| -2% | -$24.9M | 0.24% | 87 |
|
|
2025
Q1 | $1.08B | Buy |
2,235,469
+219,946
| +11% | +$102M | 0.29% | 67 |
|
|
2024
Q4 | $812M | Buy |
2,015,523
+143,713
| +8% | +$66.6M | 0.21% | 99 |
|
|
2024
Q3 | $871M | Sell |
1,871,810
-182,971
| -9% | -$87.9M | 0.22% | 93 |
|
|
2024
Q2 | $963M | Sell |
2,054,781
-170,526
| -8% | -$74M | 0.26% | 78 |
|
|
2024
Q1 | $930M | Sell |
2,225,307
-284,722
| -11% | -$120M | 0.26% | 82 |
|
|
2023
Q4 | $1.02B | Sell |
2,510,029
-427,783
| -15% | -$158M | 0.31% | 65 |
|
|
2023
Q3 | $1.02B | Sell |
2,937,812
-86,031
| -3% | -$30.1M | 0.34% | 59 |
|
|
2023
Q2 | $1.06B | Sell |
3,023,843
-366,017
| -11% | -$123M | 0.33% | 62 |
|
|
2023
Q1 | $1.07B | Sell |
3,389,860
-188,787
| -5% | -$56.6M | 0.35% | 57 |
|
|
2022
Q4 | $1.03B | Sell |
3,578,647
-463,346
| -11% | -$141M | 0.35% | 60 |
|
|
2022
Q3 | $1.17B | Sell |
4,041,993
-520,956
| -11% | -$150M | 0.43% | 41 |
|
|
2022
Q2 | $1.29B | Sell |
4,562,949
-384,414
| -8% | -$103M | 0.45% | 40 |
|
|
2022
Q1 | $1.29B | Buy |
4,947,363
+524,167
| +12% | +$124M | 0.38% | 50 |
|
|
2021
Q4 | $969M | Buy |
4,423,196
+1,034,106
| +31% | +$201M | 0.27% | 74 |
|
|
2021
Q3 | $615M | Buy |
3,389,090
+650,315
| +24% | +$127M | 0.2% | 111 |
|
|
2021
Q2 | $552M | Buy |
2,738,775
+820,708
| +43% | +$172M | 0.17% | 129 |
|
|
2021
Q1 | $412M | Buy |
1,918,067
+1,100,467
| +135% | +$242M | 0.14% | 161 |
|
|
2020
Q4 | $193M | Sell |
817,600
-22,268
| -3% | -$5.11M | 0.07% | 296 |
|
|
2020
Q3 | $228M | Sell |
839,868
-444,227
| -35% | -$123M | 0.09% | 231 |
|
|
2020
Q2 | $373M | Sell |
1,284,095
-888,799
| -41% | -$241M | 0.16% | 136 |
|
|
2020
Q1 | $517M | Sell |
2,172,894
-236,171
| -10% | -$54.2M | 0.27% | 73 |
|
|
2019
Q4 | $527M | Buy |
2,409,065
+30,299
| +1% | +$6.13M | 0.22% | 91 |
|
|
2019
Q3 | $403M | Sell |
2,378,766
-62,955
| -3% | -$11.1M | 0.18% | 114 |
|
|
2019
Q2 | $448M | Buy |
2,441,721
+78,258
| +3% | +$13.7M | 0.2% | 103 |
|
|
2019
Q1 | $435M | Sell |
2,363,463
-1,986,539
| -46% | -$367M | 0.2% | 100 |
|
|
2018
Q4 | $721M | Sell |
4,350,002
-1,393,382
| -24% | -$241M | 0.36% | 51 |
|
|
2018
Q3 | $1.11B | Sell |
5,743,384
-82,081
| -1% | -$14.6M | 0.39% | 49 |
|
|
2018
Q2 | $988M | Buy |
5,825,465
+220,446
| +4% | +$34.2M | 0.44% | 39 |
|
|
2018
Q1 | $914M | Buy |
5,605,019
+349,639
| +7% | +$57.1M | 0.41% | 42 |
|
|
2017
Q4 | $787M | Sell |
5,255,380
-176,700
| -3% | -$26.2M | 0.36% | 56 |
|
|
2017
Q3 | $826M | Sell |
5,432,080
-973,672
| -15% | -$147M | 0.39% | 49 |
|
|
2017
Q2 | $826M | Sell |
6,405,752
-1,832,449
| -22% | -$221M | 0.41% | 42 |
|
|
2017
Q1 | $901M | Sell |
8,238,201
-468,434
| -5% | -$41.2M | 0.47% | 35 |
|
|
2016
Q4 | $641M | Buy |
8,706,635
+11,204
| +0.1% | +$912K | 0.35% | 53 |
|
|
2016
Q3 | $758M | Sell |
8,695,431
-328,644
| -4% | -$31.1M | 0.42% | 43 |
|
|
2016
Q2 | $776M | Sell |
9,024,075
-379,072
| -4% | -$32.8M | 0.45% | 43 |
|
|
2016
Q1 | $747M | Sell |
9,403,147
-187,047
| -2% | -$16.9M | 0.45% | 44 |
|
|
2015
Q4 | $1.21B | Sell |
9,590,194
-571,203
| -6% | -$69M | 0.71% | 26 |
|
|
2015
Q3 | $1.06B | Buy |
10,161,397
+286,836
| +3% | +$36.9M | 0.66% | 26 |
|
|
2015
Q2 | $1.22B | Sell |
9,874,561
-81,333
| -0.8% | -$10.2M | 0.69% | 19 |
|
|
2015
Q1 | $1.17B | Buy |
9,955,894
+642,075
| +7% | +$76.9M | 0.67% | 23 |
|
|
2014
Q4 | $1.11B | Sell |
9,313,819
-184,044
| -2% | -$20.7M | 0.64% | 22 |
|
|
2014
Q3 | $1.07B | Buy |
9,497,863
+2,419,288
| +34% | +$230M | 0.64% | 21 |
|
|
2014
Q2 | $670M | Sell |
7,078,575
-1,047,185
| -13% | -$73.4M | 0.4% | 46 |
|
|
2014
Q1 | $575M | Buy |
8,125,760
+334,295
| +4% | +$26.5M | 0.35% | 63 |
|
|
2013
Q4 | $579M | Buy |
7,791,465
+1,833,313
| +31% | +$128M | 0.35% | 59 |
|
|
2013
Q3 | $452M | Buy |
5,958,152
+1,375,662
| +30% | +$109M | 0.3% | 65 |
|
|
2013
Q2 | $366M | Buy |
+4,582,490
| New | +$337M | 0.25% | 81 |
|
Other funds holding VRTX
VCM
VPM
Ameriprise's VRTX Position: Q1 2026 in Review
Ameriprise increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, buying an estimated $172M and bringing the position to 2,633,481 shares worth $1.18B. The position accounts for 0.27% of the portfolio, ranked #81.
Ameriprise first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.29B in Q1 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Ameriprise held 2,633,481 shares of Vertex Pharmaceuticals worth $1.18B as of Q1 2026.
- Ameriprise bought 369,749 Vertex Pharmaceuticals shares in Q1 2026, an estimated $172M.
- Vertex Pharmaceuticals made up 0.27% of Ameriprise's portfolio in Q1 2026, its #81 holding.
- Ameriprise first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Ameriprise's Vertex Pharmaceuticals position peaked at $1.29B in Q1 2022.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.